Official Title
Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Multicenter European Study
Brief Summary

This study aims to investigate outcomes and predictors of outcome after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory syndrome (ARDS) in COVID-19 patients.

Detailed Description

We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related
acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane
oxygenation (ECMO).

Status
Completed
Conditions
COVID-19
Extracorporeal Membrane Oxygenation Complication
Acute Respiratory Distress Syndrome
Interventions

Device: Extracorporeal membrane oxygenation

Veno-venous or veno-arterial extracorporeal oxygenation

Eligibility Criteria

Inclusion Criteria:

- PCR-confirmed or suspected COVID-19 infection with ARDS who require any ECMO therapy

Exclusion Criteria:

- None

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
Finland
France
Germany
Italy
Sweden
United Kingdom
Locations

Helsinki University Hospital
Helsinki, Finland

University Hospital Jean Minjoz
Besançon, France

Nancy University Hospital
Nancy, France

Henri Mondon Unoversity Hospital
Paris, France

Robert Debré University Hospital
Reims, France

Hamburg University Heart Center
Hamburg, Germany

Münster University Hospital
Münster, Germany

S. Orsola Hospital
Bologna, Italy

Lecco Hospital
Lecco, Italy

Karolinska University Hospital
Stockholm, Sweden

University Hospitals of Leicester
Leicester, United Kingdom

Investigators

Fausto Biancari, Professor, Principal Investigator
Helsinki University Central Hospital

Sponsors / Collaborators
Helsinki University Central Hospital
NCT Number
NCT04383678
MeSH Terms
COVID-19
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Syndrome